DK1334964T3 - Fremgangsmåde til fremstilling af nateglinidkrystaller med B form - Google Patents

Fremgangsmåde til fremstilling af nateglinidkrystaller med B form

Info

Publication number
DK1334964T3
DK1334964T3 DK01976819T DK01976819T DK1334964T3 DK 1334964 T3 DK1334964 T3 DK 1334964T3 DK 01976819 T DK01976819 T DK 01976819T DK 01976819 T DK01976819 T DK 01976819T DK 1334964 T3 DK1334964 T3 DK 1334964T3
Authority
DK
Denmark
Prior art keywords
nateglinide
crystals
preparation
type crystals
nateglinide crystals
Prior art date
Application number
DK01976819T
Other languages
Danish (da)
English (en)
Inventor
Michito Sumikawa
Makoto Maruo
Kazuo Miyazaki
Shigehiro Nishina
Yukiko Matsuzawa
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of DK1334964T3 publication Critical patent/DK1334964T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01976819T 2000-10-24 2001-10-23 Fremgangsmåde til fremstilling af nateglinidkrystaller med B form DK1334964T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (fr) 2000-10-24 2001-10-23 Procede de production de cristaux de nateglinide a forme b

Publications (1)

Publication Number Publication Date
DK1334964T3 true DK1334964T3 (da) 2007-09-24

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01976819T DK1334964T3 (da) 2000-10-24 2001-10-23 Fremgangsmåde til fremstilling af nateglinidkrystaller med B form

Country Status (18)

Country Link
US (2) US20030229249A1 (zh)
EP (1) EP1334964B1 (zh)
JP (1) JP4225057B2 (zh)
KR (1) KR100810930B1 (zh)
CN (1) CN100422143C (zh)
AT (1) ATE370115T1 (zh)
AU (1) AU2001296001A1 (zh)
BR (1) BR0114846A (zh)
CA (1) CA2426745C (zh)
CY (1) CY1106839T1 (zh)
DE (1) DE60130014T2 (zh)
DK (1) DK1334964T3 (zh)
ES (1) ES2288997T3 (zh)
MX (1) MXPA03003575A (zh)
PT (1) PT1334964E (zh)
RU (1) RU2275354C2 (zh)
TW (1) TWI293290B (zh)
WO (1) WO2002034713A1 (zh)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02009130A (es) * 2000-03-17 2003-03-12 Ajinomoto Kk Farmacos para complicaciones de diabetes y neuropatia y utilizacion de los mismos.
WO2002032853A1 (fr) * 2000-10-18 2002-04-25 Ajinomoto Co.,Inc. Procede de preparation d'acylphenylalanines
CN100384814C (zh) * 2000-10-18 2008-04-30 味之素株式会社 那格列胺结晶的制备方法
ATE406885T1 (de) * 2000-10-24 2008-09-15 Ajinomoto Kk Nateglinid enthaltende präparate
EP1334721B1 (en) * 2000-10-24 2009-04-22 Ajinomoto Co., Inc. Nateglinide-containing hydrophilic drug preparations
AU2003236243A1 (en) * 2002-04-15 2003-10-27 Ajinomoto Co., Inc. Novel nateglinide crystal
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
JP2006511614A (ja) * 2002-07-18 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ナテグリニドの多形性形状
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
ATE349418T1 (de) * 2003-11-26 2007-01-15 A M S A Anonima Materie Sint E Verfahren zur herstellung von nateglinidin der b- form
US20060004102A1 (en) * 2004-05-07 2006-01-05 Shlomit Wizel Polymorphic forms of nateglinide
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles
WO2005113485A2 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Stable nateglinide form b compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
US9150499B2 (en) 2010-06-14 2015-10-06 Cipla Limited Process for the preparation of nateglinide
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167987A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of diabetes
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
JP2508949B2 (ja) * 1991-07-30 1996-06-19 味の素株式会社 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶及びその製造法
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE69735644T2 (de) * 1996-11-15 2007-05-03 Ajinomoto Co., Inc. Nateglinide zubereitung in tablettenform
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
ATE399000T1 (de) * 1999-12-28 2008-07-15 Ajinomoto Kk Antidiabetes-zubereitung zur oralen verabreichung
MXPA02009130A (es) * 2000-03-17 2003-03-12 Ajinomoto Kk Farmacos para complicaciones de diabetes y neuropatia y utilizacion de los mismos.
CN100384814C (zh) * 2000-10-18 2008-04-30 味之素株式会社 那格列胺结晶的制备方法
WO2002032853A1 (fr) * 2000-10-18 2002-04-25 Ajinomoto Co.,Inc. Procede de preparation d'acylphenylalanines
ATE406885T1 (de) * 2000-10-24 2008-09-15 Ajinomoto Kk Nateglinid enthaltende präparate
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
EP1334964B1 (en) 2007-08-15
KR100810930B1 (ko) 2008-03-10
TWI293290B (zh) 2008-02-11
ATE370115T1 (de) 2007-09-15
JP4225057B2 (ja) 2009-02-18
EP1334964A4 (en) 2005-09-28
PT1334964E (pt) 2007-09-20
BR0114846A (pt) 2004-02-25
ES2288997T3 (es) 2008-02-01
AU2001296001A1 (en) 2002-05-06
RU2275354C2 (ru) 2006-04-27
WO2002034713A1 (fr) 2002-05-02
DE60130014T2 (de) 2008-05-08
MXPA03003575A (es) 2003-07-14
US20030229249A1 (en) 2003-12-11
CN100422143C (zh) 2008-10-01
CN1483018A (zh) 2004-03-17
US7544834B2 (en) 2009-06-09
EP1334964A1 (en) 2003-08-13
CA2426745A1 (en) 2003-04-23
CY1106839T1 (el) 2012-05-23
US20070232829A1 (en) 2007-10-04
DE60130014D1 (de) 2007-09-27
KR20030059212A (ko) 2003-07-07
JPWO2002034713A1 (ja) 2004-03-04
CA2426745C (en) 2009-09-15

Similar Documents

Publication Publication Date Title
DK1334964T3 (da) Fremgangsmåde til fremstilling af nateglinidkrystaller med B form
RU2003111948A (ru) Способы получения кристаллов в-типа натеглинида
HUP0004325A2 (hu) 2-(3-Ciano-4-izobutiloxifenil)-4-metil-5-tiazolkarbonsav polimorf módosulatai és eljárás ezek előállítására
DK1309547T3 (da) Krystallinsk og ren modafinil og fremgangsmåde til fremstilling af samme
ATE396551T1 (de) Verfahren zur verringerung des stromverbrauchs in bluetooth- und cdma-betriebsarten
DK0892792T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1337525T3 (da) Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol
WO2003014080A3 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
DK1341749T3 (da) Fremgangsmåde til fremstilling af gabapentin
DK1272489T3 (da) Fremgangsmåde til præparation af cabergolins krystallinske form I
ATE443069T1 (de) Verfahren zur herstellung von chlorotris (triphenylphosphan)rhodium (i)
DE60032358D1 (de) Verfahren zur herstellung von si-sic-gliedern zur thermischen behandlung von halbleitern
DK1644469T4 (da) Fremgangsmåde til fremstilling af oprensede fedtsyrer
DE60204920D1 (de) Magneteinheit für Beton-Schalungen
AR045836A1 (es) Proceso para preparar y purificar mesotriona
DK1873152T3 (da) Hidtil ukendt fremgangsmåde til oprensning af Moxonidin
DE60008278D1 (de) Verbessertes verfahren zur herstellung von trifluorpropanal und seinem oxim
JP2001288147A5 (zh)
DE69925836D1 (de) Ein verfahren zur herstellung von 4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-carbonsäure
DE60035241D1 (de) Luftwäscher
IS6224A (is) Aðferð til kristöllunar N- (1(S)-etoxýkarbonýl-3-fenýlprópýl)-L-alanín-N-karboxýlanhýdríðs
WO2006102176A3 (en) Process for preparing crystalline form i of olanzapine
HUP0200058A2 (hu) Eljárás N-(4-trifluor-metil-fenil)-5-metil-izoxazol-4-karboxamid kristályosítására
DE602005019819D1 (de) Verfahren zur Herstellung von Stickstofftrifluorid
ATE327218T1 (de) Verfahren zur herstellung von 1-methyl-3- nitroguanidin